We successfully treated 5 patients with seborrheic dermatitis using Kampo medicine. Three of these patients presented with facial the lesions which had persisted for 1 to 2 years despite their having received treatment with steroid ointments or ketokonazol lotions. We treated these patients with jumihaidokuto and they recovered significantly within a few months. The two remaining patients presented with scalp lesions, which had persisted for10and 25 years respectively. We treated them with a combined formulation of keigairengyoto, makyoyokukanto and yokukansankachimpihange, and they improved remarkably after 2 and 8 months respectively.
Medicine, Kampo ; Seborrheic dermatitis ; Cases ; seconds ; month

Objective: Breast cancer susceptibility gene 1 (BRCA1)-associated ovarian cancer patients have been treated with A poly (ADP-ribose) polymerase (PARP) inhibitor, extending the progression-free survival; however, they finally acquire therapeutic resistance. Interleukin (IL)-34 has been reported as a poor prognostic factor in several cancers, including ovarian cancer, and it contributes to the therapeutic resistance of chemotherapies. IL-34 may affect the therapeutic effect of PARP inhibitor through the regulation of tumor microenvironment (TME). Methods: In this study, The Cancer Genome Atlas (TCGA) data set was used to evaluate the prognosis of IL-34 and human ovarian serous carcinoma. We also used CRISPR-Cas9 genome editing technology in a mouse model to evaluate the efficacy of PARP inhibitor therapy in the presence or absence of IL-34. Results: We found that IL34 was an independent poor prognostic factor in ovarian serous carcinoma, and its high expression significantly shortens overall survival. Furthermore, in BRCA1-associated ovarian cancer, PARP inhibitor therapy contributes to anti-tumor immunity via the XCR1+ DC-CD8+ T cell axis, however, it is canceled by the presence of IL-34. Conclusion These results suggest that tumor-derived IL-34 benefits tumors by creating an immunosuppressive TME and conferring PARP inhibitor therapeutic resistance. Thus, we showed the pathological effect of IL-34 and the need for it as a therapeutic target in ovarian cancer.